Biotech Values

[DewDiligence]

AZN talks up pipeline (while continuing to reject PFE’s sweetened ofer):

http://online.wsj.com/news/articles/SB10001424052702304831304579545330367321414

New sales estimates AstraZeneca gave Tuesday for its pipeline drugs include up to $6.5 billion for its biggest hope: new cancer treatment MEDI4736, compared with analyst estimates of $2 billion to $7 billion cited by the company.

AstraZeneca also set out new revenue targets for its five growth areas. Annual revenue estimates for 2023 now include $3.5 billion from its blood-thinning pill Brilinta, $8 billion from its portfolio of diabetes drugs and $8 billion from respiratory drugs. The company said it expects mid-to-high-single-digit percentage revenue growth in emerging markets and low-single-digit revenue growth in Japan.

The $3.5B target for Brilinta will be tough to meet, IMO.